BioSpace News Archive

KIYATEC Announces Investment from Seae Ventures and Names Co-founder and Managing Partner Jason Robart to its Board of Directors

KIYATEC, Inc announced today that it secured a $2.5 million investment from Boston-based healthcare service and technology venture capital fund Seae Ventures.

April 30, 2021
·
2 min read
Business

Coherus BioSciences to Report First Quarter 2021 Financial Results on May 6th

Coherus BioSciences, Inc. (“Coherus” or “the Company”, Nasdaq: CHRS), today announced that its first quarter 2021 financial results will be released after market close on Thursday, May 6, 2021. Starting at 4:30 p.m. ET,

April 30, 2021
·
1 min read
Business

Alexion Reports First Quarter 2021 Results

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced financial results for the first quarter of 2021. Total revenues in the first quarter were $1,636.5 million, a 13 percent increase compared to the same period in 2020.

April 30, 2021
·
30 min read
Pharm Country

Delcath Systems Announces Oral Presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting

Delcath Systems, Inc. (Nasdaq: DCTH ), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, today announced an oral presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting to be held virtually June 4-8, 2021,

April 30, 2021
·
2 min read
Drug Development

Praxis Precision Medicines Receives Orphan Drug Designation for PRAX-562 for the Treatment of SCN2A-DEEPRAX-562 Phase 2 clinical trial for treatment of DEEs expected to initiate in first half of 2022

Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system disorders (CNS) characterized by neuronal imbalance, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to PRAX-562 for the treatment of SCN2A development and epileptic encephalopathy (SCN2A-DEE).

April 30, 2021
·
3 min read
Therapeutic Solutions International Comes to Agreement with FDA on Clinical Trial Design for First Stem Cell Clinical Trial in Chronic Traumatic Encephalopathy (CTE) Patients

Therapeutic Solutions International, Inc., (OTC Markets: TSOI), announced today receipt of a written communication from the Food and Drug Administration (FDA) regarding its Investigational New Drug (IND) application, which was granted number 27377.

April 30, 2021
·
2 min read
Pharm Country

AMRI Adds to Accelerated R&D and Manufacturing Solutions for Orphan Products to Treat Rare Diseases

Albany Molecular Research, Inc. (AMRI), a leading global provider of advanced contract research, development and manufacturing solutions, today announced expanded access to its accelerated solutions platform, spanning research & development to manufacturing for orphan and rare disease products.

April 30, 2021
·
3 min read
Bio NC

Illingworth Research Group Recognized with Queen’s Award for Enterprise: International Trade 2021

The Illingworth Research Group, a Syneos Health® company, has been recognized with a 2021 Queen’s Award for Enterprise for International Trade.

April 30, 2021
·
3 min read
BioMidwest

NuvOx Completes Construction of Expanded Manufacturing Facility.

NuvOx Pharma has completed construction and initiated operation of its GMP production facility for manufacturing its injectable pharmaceutical products at its Tucson, Arizona facility.

April 30, 2021
·
2 min read
Pharm Country

Eagle Pharmaceuticals Announces TREAKISYM (bendamustine) Ready-to-Dilute (“RTD”) Formulation

-Eagle believes new indication could allow for a significant expansion of the overall market opportunity- -RTD and Rapid Infusion (“RI”) formulations anticipated to generate approximately $25 million of combined royalty and milestone revenue at peak-

April 30, 2021
·
5 min read